Results 101 to 110 of about 6,304,439 (300)

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer

Signal Transduction and Targeted Therapy
Neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy represents the current standard-of-care for HER2-positive breast cancer.
Xiang-Rong Wu, Hong Lv, Shen Zhao, Xiao-Hua Zeng, Lei-Jie Dai, Yu-Zheng Xu, Yu-Wei Li, Zi-Yu Qiu, Ji-Ting Huang, Ning-Ning Zhang, Li Chen, Min He, Yi-Zhi Zhao, Lin Yang, Tong Zhou, Jun-Jie Li, Jiong Wu, Yi-Zhou Jiang, Wen-Tao Yang, Gen-Hong Di, Zhi-Ming Shao, Ding Ma   +21 more
doaj   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study

BMC Medicine
Background The efficacy and safety of anti-HER2 therapy and immune checkpoint inhibitors combined with chemotherapy to treat HER2-positive advanced breast cancer that has failed standard HER2-directed therapies is unknown.
Huimin Lv, Tao Sun, Xiaoling Ling, Xinlan Liu, Jin Yang, Mengwei Zhang, Limin Niu, Shumin Chen, Zhenzhen Liu, Chengzheng Wang, Huihui Sun, Jing Wang, Huiai Zeng, Shengnan Zhao, Lanwei Guo, Yajing Feng, Zhiqing Zhang, Qingxin Xia, Rongguo Qiu, Min Yan   +19 more
doaj   +1 more source

Cancer of the Breast [PDF]

Postgraduate Medical Journal, 1939
openaire   +3 more sources

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study

npj Breast Cancer
Pregnancy-associated breast cancer (PABC), diagnosed during or shortly after pregnancy, is a challenging entity with an aggressive biology and poor prognosis.
Regina Peña-Enríquez, Begoña Bermejo, Marina Pollán, Alejandra Díaz-Chacón, Yolanda Jerez Gilarranz, José J Ponce Lorenzo, Antonio Fernández Aramburo, Blanca Cantos Sánchez de Ibargüen, Ana Santaballa Bertrán, Elena Galve-Calvo, Álvaro Jiménez-Arranz, Yolanda Fernández, María Eva Pérez, Susana De La Cruz, Antonio Anton-Torres, Fernando Moreno, María Jesús Vidal-Losada, María Helena López-Ceballos, Isabel Blancas, María José Echarri, Raúl Rincón, Rosalía Caballero, Ángel Guerrero-Zotano, Silvia Guil-Luna, Juan de la Haba-Rodríguez   +24 more
doaj   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer

Breast Cancer: Targets and Therapy
Zhenyu Zhang,1,2,* Zhengrui Liu,1,2,* Chao Li,1 Fukai Wang,1 Zhaokun Tian,1 Xiaoyu Liu,1 Zhiyong Yu1 1Breast Surgery Ward Three, Shandong Cancer Hospital and Institute, Jinan, 250117, People’s Republic of China; 2Shandong First Medical ...
Zhang Z, Liu Z, Li C, Wang F, Tian Z, Liu X, Yu Z   +6 more
doaj